News - Page 68 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Adapting to the Squeeze: Spending Trends, Slimming Pipelines, M&A and Partnerships in 2022

Adapting to the Squeeze: Spending Trends, Slimming Pipelines, M&A and Partnerships in 2022

Post published:January 26, 2023
Post category:2022 Year in Review

Read more about the article Psychedelic Investor Pulse Survey – Q4 2022

Psychedelic Investor Pulse Survey – Q4 2022

Post published:January 26, 2023
Post category:2022 Year in Review

Read more about the article MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023

Post published:January 25, 2023
Post category:Press Release

Read more about the article Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Post published:January 25, 2023
Post category:Press Release

Read more about the article Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Post published:January 25, 2023
Post category:Press Release

Read more about the article Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Post published:January 25, 2023
Post category:Press Release

Read more about the article GH Research Provides Business Updates and Highlights Key Upcoming Milestones

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Post published:January 25, 2023
Post category:Press Release

Read more about the article Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Post published:January 24, 2023
Post category:Press Release

Read more about the article Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Post published:January 24, 2023
Post category:Press Release

Read more about the article Panel: Three Psychedelics Companies that Raised in 2022

Panel: Three Psychedelics Companies that Raised in 2022

Post published:January 24, 2023
Post category:2022 Year in Review

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.